{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Soltyka-Krajewska M"],"funding":["National Science Centre in Poland"],"pagination":["2240"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11504489"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(10)"],"pubmed_abstract":["Background
One defining feature of various aggressive cancers, including glioblastoma multiforme (GBM), is glycolysis upregulation, making its inhibition a promising therapeutic approach. One promising compound is 2-deoxy-d-glucose (2-DG), a d-glucose analog with high clinical potential due to its ability to inhibit glycolysis. Upon uptake, 2-DG is phosphorylated by hexokinase to 2-DG-6-phosphate, which inhibits hexokinase and downstream glycolytic enzymes. Unfortunately, therapeutic use of 2-DG is limited by poor pharmacokinetics, suppressing its efficacy.Methods
To address these issues, we synthesized novel halogenated 2-DG analogs (2-FG, 2,2-diFG, 2-CG, and 2-BG) and evaluated their glycolytic inhibition in GBM cells. Our in vitro and computational studies suggest that t"],"journal":["Biomedicines"],"pubmed_title":["Potent Biological Activity of Fluorinated Derivatives of 2-Deoxy-d-Glucose in a Glioblastoma Model."],"pmcid":["PMC11504489"],"funding_grant_id":["UMO-2017/25/B/NZ3/00251"],"pubmed_authors":["Pajak-Tarnacka B","Ziemniak M","Jaskiewicz A","Soltyka-Krajewska M","Zielinski R","Kozminski W","Skora S","Wozniak K","Zawadzka-Kazimierczuk A","Siwiak-Niedbalska E","Priebe W","Skrzypczyk P","Fokt I"],"additional_accession":[]},"is_claimable":false,"name":"Potent Biological Activity of Fluorinated Derivatives of 2-Deoxy-d-Glucose in a Glioblastoma Model.","description":"Background
One defining feature of various aggressive cancers, including glioblastoma multiforme (GBM), is glycolysis upregulation, making its inhibition a promising therapeutic approach. One promising compound is 2-deoxy-d-glucose (2-DG), a d-glucose analog with high clinical potential due to its ability to inhibit glycolysis. Upon uptake, 2-DG is phosphorylated by hexokinase to 2-DG-6-phosphate, which inhibits hexokinase and downstream glycolytic enzymes. Unfortunately, therapeutic use of 2-DG is limited by poor pharmacokinetics, suppressing its efficacy.Methods
To address these issues, we synthesized novel halogenated 2-DG analogs (2-FG, 2,2-diFG, 2-CG, and 2-BG) and evaluated their glycolytic inhibition in GBM cells. Our in vitro and computational studies suggest that t","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2026-07-08T03:19:02.254Z","creation":"2025-04-04T11:42:54.363Z"},"accession":"S-EPMC11504489","cross_references":{"pubmed":["39457553"],"doi":["10.3390/biomedicines12102240"]}}